XNASIKT
Market cap184mUSD
Jan 14, Last price
2.66USD
1D
0.00%
1Q
37.11%
IPO
-95.48%
Name
Inhibikase Therapeutics Inc
Chart & Performance
P/E
—
P/S
708.27
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.90%
Rev. gr., 5y
-42.21%
Revenues
261k
+111.03%
Net income
-19m
L+6.28%
CFO
-18m
L+4.23%
Earnings
Mar 25, 2025
Profile
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 260 111.03% | 123 -96.02% | ||||||
Cost of revenue | 27,237 | 12,042 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (26,976) | (11,918) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (149) | |||||||
Tax Rate | ||||||||
NOPAT | (26,976) | (11,769) | ||||||
Net income | (19,029) 6.28% | (17,905) 20.93% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 8,544 | 44 | ||||||
BB yield | -126.14% | -0.35% | ||||||
| Debt | ||||||||
Debt current | 532 | 146 | ||||||
Long-term debt | 330 | 557 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (12,390) | (22,348) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (18,085) | (17,351) | ||||||
CAPEX | (14) | (243) | ||||||
Cash from investing activities | 11,657 | (16,006) | ||||||
Cash from financing activities | 8,405 | (205) | ||||||
FCF | (26,707) | (12,335) | ||||||
| Balance | ||||||||
Cash | 13,252 | 23,050 | ||||||
Long term investments | ||||||||
Excess cash | 13,239 | 23,044 | ||||||
Stockholders' equity | (66,894) | (47,742) | ||||||
Invested Capital | 78,494 | 69,129 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 5,333 | 4,202 | ||||||
Price | 1.27 -57.67% | 3.00 -65.99% | ||||||
Market cap | 6,773 -46.27% | 12,606 -52.91% | ||||||
EV | (5,617) | (9,742) | ||||||
EBITDA | (26,799) | (11,912) | ||||||
EV/EBITDA | 0.21 | 0.82 | ||||||
Interest | 74 | |||||||
Interest/NOPBT | ||||||||